CCA CATO Associate Investigational Product Management 2 — Questions and Answers
Question 1: What is the purpose of a drug reconciliation at the end of a clinical trial?
- To determine the study's statistical power
- To verify that all dispensed, returned, and destroyed IP quantities balance with what was received (Correct answer)
- To prepare the clinical study report
- To finalize site payment invoices
Correct answer: To verify that all dispensed, returned, and destroyed IP quantities balance with what was received
Drug reconciliation confirms that all IP received is accounted for through dispensing records, subject returns, and destruction documentation.
Question 2: What is a 'medication error' in the context of investigational product management?
- Any deviation from the IP storage requirements
- Any unintended exposure of a subject to the wrong IP dose, route, or product (Correct answer)
- An IP shipment that arrives late
- A missing drug accountability entry
Correct answer: Any unintended exposure of a subject to the wrong IP dose, route, or product
A medication error is any unintended deviation in the administration of IP—wrong dose, wrong route, wrong subject, or wrong product.
Question 3: What does 'blinded randomization' require of the IP packaging and labeling?
- Active and placebo must be labeled with the subject's name
- Active and placebo must be indistinguishable in appearance and labeled with only a randomization code (Correct answer)
- All kits must display the treatment name
- Labels must include the IND number
Correct answer: Active and placebo must be indistinguishable in appearance and labeled with only a randomization code
Blinded trial packaging requires active and placebo to look identical, with labels bearing only a code so that neither site staff nor subjects can identify the treatment.
Question 4: Under GCP, how long must IP accountability records typically be retained after the trial ends?
- 1 year
- 2 years
- Per sponsor/regulatory requirements, typically at least 2–15 years depending on jurisdiction (Correct answer)
- 30 days
Correct answer: Per sponsor/regulatory requirements, typically at least 2–15 years depending on jurisdiction
IP accountability records must be retained per applicable regulatory requirements and sponsor instructions, commonly ranging from 2 to 15+ years.
Question 5: When a clinical site receives a shipment of investigational product, what should be done first?
- Immediately dispense to the next eligible subject
- Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit (Correct answer)
- Enter the receipt in the CRF
- Notify the IRB of the new supply
Correct answer: Inspect the shipment, verify contents against the packing list, and check storage conditions were maintained during transit
Upon IP receipt, the site must inspect the shipment for damage, verify quantities against the packing list, and confirm transit temperature logs before accepting the product.
Question 6: What is an 'emergency unblinding' procedure in the context of IP management?
- Routine disclosure of treatment assignments at study end
- A process allowing rapid disclosure of a subject's treatment assignment when medically necessary (Correct answer)
- Destruction of IP at close-out
- Transfer of IP to another site
Correct answer: A process allowing rapid disclosure of a subject's treatment assignment when medically necessary
Emergency unblinding allows rapid determination of a subject's treatment assignment when knowledge is essential for the subject's medical management.
CCA CATO Associate Investigational Product Management 2
What is the purpose of a drug reconciliation at the end of a clinical trial?